Influenza viruses are a major cause of upper respiratory tract infections and are responsible for epidemic outbreaks during the winter months. These seasonal influenza epidemics are caused by currently circulating human influenza A and B viruses. For certain patients who are at a high risk of complications due to influenza, annual vaccination against influenza is recommended. Currently used inactivated vaccines are mostly efficacious and reduce morbidity and mortality provided that the strains used for vaccine production match the epidemic strains. Occasionally, novel subtypes of influenza A viruses are introduced into the human population. These new subtypes originate from the avian reservoir of all subtypes of influenza A viruses [1]. Since the human population has never been exposed to these novel subtypes, these viruses can replicate in their new host without the interference of pre-existing virus-neutralizing antibodies. Under these circumstances, new viruses can cause worldwide influenza epidemics, also known as pandemics, with considerable morbidity and mortality in the human population. In the last century, three pandemics occurred, caused by influenza A viruses of the H1N1, H2N2 and H3N2 subtypes [2].

Currently, influenza A viruses of the H5N1 subtype pose a pandemic threat because transmissions from infected birds to humans have been reported during outbreaks of highly pathogenic avian influenza (HPAI) in poultry since 1997 [3–5].

Since 2003, 387 human cases have been reported, of which more than 60% were fatal [101]. So far, these viruses do not spread efficiently from human to human, although sporadic clusters of human-to-human transmissions have been described [6–8].

When the HPAI viruses acquire the necessary adaptations to cause sustained human-to-human transmission, they may cause a future pandemic outbreak [9]. To limit the impact of such an outbreak, the availability of safe and effective vaccines is desirable and considered a high priority by the WHO [102]. Major efforts have been made to prepare such H5N1 vaccines. However, there were a number of issues that complicated the development of such vaccines, including poor vaccine immunogenicity, long response time, limited production capacity and antigenic variation of circulating strains [103].

Recall that MVA is attractive and promising as a novel viral vector for the expression of foreign genes of interest because it possesses unique properties. In particular, its excellent safety profile and the availability of versatile vector technologies have frequently made MVA the vaccine virus of choice for preclinical and clinical studies. Owing to its avirulence and deficiency to productively replicate after in vivo inoculation, MVA can be used under biosafety level 1 conditions. In addition to a better safety profile than replication competent vaccinia viruses, the use of MVA leads to similar levels of gene expression and has better immunostimulatory properties and improved efficacy as a recombinant vaccine. In animal models, recombinant MVA vaccines were immunogenic and induced protective immunity against various infectious agents, including viruses, bacteria and parasites. Here we review the progress that has been made in the development of recombinant MVA as a viral vector and candidate pandemic influenza H5N1 vaccine. Specifically, we will focus on the preclinical evaluation of recombinant MVA vector as pandemic influenza A/H5N1 vaccine candidates and discuss the possible future approaches for the use of these novel MVA-based vaccines.

**Keywords:** influenza virus • modified vaccinia virus • pandemic • vaccine
Some important developments have been made during the last decade. A review by Kreijtz et al. addresses some of these issues, such as the development of rapid procedures to produce vaccine strains (reverse genetics), cell culture technology to produce vaccine independent of embryonated chicken eggs and the development of adjuvants that increase the immunogenicity of conventional vaccine preparations and that would facilitate dose sparing [10]. Here, we discuss modified vaccinia virus Ankara (MVA) as a viral vector for the delivery of influenza virus antigens as a promising technology that addresses most of the issues outlined above.

MVA: a replication-deficient poxvirus vector

Modified vaccinia virus Ankara is an attenuated strain of vaccinia virus that was originally developed for use as safer vaccine during the last decades of the smallpox eradication campaign [11,12]. Indeed, MVA was chosen by the Bavarian State Vaccine Institute in Munich (Germany) as a basis for the evaluation of new vaccine preparations and vaccination strategies against smallpox [13,14]. From 1968 to 1988, MVA immunizations were administered to more than 120,000 individuals in Germany without significant adverse events. The excellent safety profile is also observed in the more recent clinical trials aiming at the approval of MVA as a next-generation smallpox vaccine [15-17]. The extraordinary safety profile was exemplified in studies with immunocompromized macaques. Macaques from which T lymphocytes were depleted by treatment with anti-thymocyte globulin or that received a total-body irradiation were subsequently vaccinated with a high dose of MVA. In these severely immunocompromized animals, the virus did not replicate and did not lead to generalized infection normally seen with wild-type, replication-competent vaccinia viruses [18].

After genetic modification of MVA (i.e., insertion of foreign genes under the control of a vaccinia virus promoter), its potential as viral vector was recognized after demonstrating that MVA can efficiently express foreign genes of interest in nonpermissive human cells [19]. At present, recombinant MVA serves as a vaccine-development platform due to its clinical safety and its potency to induce robust immune responses against heterologous antigens [20-22]. Various recombinant MVA vaccines are currently being evaluated in clinical trials, mostly aiming for prophylaxis or therapy of infectious diseases and cancers against which no vaccine is available [23-27]. The wealth of information that has been obtained from a vast and ever-increasing body of basic and clinical research with MVA vector vaccines has provided answers to important questions related to the development and use of viral vector vaccines. One of these questions relates to the influence of pre-existing antivector immunity and the possibility to repeatedly administer the same vector expressing the same or other antigens. Of course, the potential interference with vaccination by pre-existing antivector antibodies is a concern. However, it is of special interest to note that MVA vector vaccines differ in this respect from many other viral vectors that are not effective in the presence of pre-existing antibodies and that induce antibodies against the vaccine antigen of interest inefficiently upon a second administration of the same vector.

Preclinical evaluation of MVA vectors already demonstrated its capacity to repeatedly boost immune responses directed to the recombinant antigens. This suggests that immunization with nonreplicating MVA resembles immunization with inactivated vaccines more than with replicating live vaccines, which are more sensitive to antivector immunity [28]; for a review of this see [21,22]. Recently, the first encouraging data have been obtained from the therapeutic immunization of humans [29]. This Phase II clinical trial in colorectal cancer patients tested the immunogenicity of six consecutive applications of a MVA vector encoding the tumor antigen 5T4. Despite efficient induction of MVA-specific antibodies already peaking to high levels after the second vaccination, the antibody responses to 5T4 were boosted after each vaccination, with the highest levels found after the fifth and sixth immunization. Thus, vector-specific antibodies do not seem to have a major impact on the induction of antibody responses specific for the target antigen by repeated administration of recombinant MVA vaccines.

Yet, pre-existing antivector immunity may have a greater influence on target antigen-specific CD8+ T-cell responses. Data from MVA vector immunizations with simian immunodeficiency virus antigens in the macaque model firstly suggested that three prior applications of MVA vaccine limited the levels of Gag epitope-specific CD8+ T cells induced by a fourth immunization [30]. MVA delivery of the Ebola virus glycoprotein (GP) in the mouse model demonstrated that prevaccination with replication-competent vaccinia virus inhibited cellular (cytotoxic T cell) but not humoral immune responses to GP [31]. Interestingly, such hindrance of MVA immunogenicity by pre-existing vaccinia-specific immunity could be largely overcome by priming with a GP-specific DNA vaccine [31] or by the use of a new oral vaccination with recombinant MVA attached to TMPEG-modified cationic liposomes [32].

With regard to the induction of T-cell immunity, evidence is accumulating that recombinant MVA vaccines can induce more balanced antigen-specific CD4+ and CD8+ T-cell responses in animal models than other poxviral or adenoviral vectors that elicit either dominant CD4+ or CD8+ antigen-specific T-cell responses [33,34]. Typically, MVA-induced CD4+ T-cell responses are being characterized predominantly as Th1 like [35], which fits well with the recent finding that MVA vector vaccination can be used to protect against allergic sensitization [36]. Strong CD8+ T-cell responses directed against the target antigens were consistently found with various heterologous vaccine prime–MVA boost protocols (first shown with DNA vaccines) [23,24,37,38]. To most efficiently elicit CD8+ T-cell responses with MVA vectors, the delivery of full-length antigen was found to be superior to the expression of peptide antigens or rapidly degradable proteins [39]. These data suggest that the particular importance of cross-priming in MVA-mediated antigen presentation and appears to correlate with recent clinical findings from HIV-1-specific DNA/MVA prime–boost vaccinations in humans [23,40]. Recombinant MVA vaccines expressing HIV proteins as antigens were highly immunogenic, in contrast to more disappointing responses that were elicited by MVA expressing a HIV-1
fusion protein consisting of a string of CD8+ T-cell peptide epitopes [40]. Finally, a long-standing observation is that non-replicating MVA vectors seem to be paradoxically immunogenic in comparison with fully replication-competent vaccinia viruses, which are able to deliver overall drastically higher amounts of antigen upon administration in vivo [41,42]. Further evidence supports the notion that MVA has particular immunostimulatory properties [43–45]. Recent experiments in mouse models revealed the in vivo synthesis of substantial amounts of type I interferon shortly after MVA vaccine administration and an activation of dendritic cells by both Toll-like receptor (TLR)-9-dependent and TLR-independent pathways [46,47]. Moreover, MVA infection of human monocyte-derived cells can induce or upregulate the expression of genes for host molecules involved in antigen uptake, cytokines, cytokine receptors, chemokines and chemokine receptors [48,49].

New developments in MVA vector generation & vaccine production

The generation of MVA vectors is straightforward, requiring genomic insertion of heterologous gene-expression cassettes. In most cases, this is achieved by homologous recombination between the MVA genome and DNA from a plasmid that carries recombinant gene sequences being placed under the control of poxvirus-specific promoters. Subsequently, the MVA vector viruses are to be clonally isolated, a procedure that is helped by well-established selection techniques [50]. Concerning influenza candidate vaccines, a very rapid generation of recombinant MVA might be desirable. Recent advances in methodology are likely to significantly shorten the time window required to obtain MVA vectors. One particularly well-performing protocol takes advantage of selective propagation on rabbit kidney RK-13 cells [51]. Another elegant method is based on the achievement to clone and engineer the entire vaccinia virus genome within a bacterial artificial chromosome (BAC) [52] and application of this BAC technology might well be an additional viable route to a more rapid and efficient generation of MVA recombinant vaccines [53].

The first MVA vaccines to be used in humans were propagated in embryonated chicken eggs or in cultures of primary chicken embryo fibroblasts (CEFs) [14]. As of today, CEF cultures are still the preferred and sole substrate for the production of MVA (vector) vaccines and, among vaccine producers, there is considerable experience in the manufacture and use of other live virus vaccines against human infections (e.g., measles and mumps). Due to the highly active development of MVA as new third-generation smallpox vaccine, MVA propagation in CEF has been adapted to a large-scale process by Bavarian Nordic [104]. In its manufacturing facility in Kvistgard, Denmark, this company reportedly uses CEF cell lines grown in suspension in Wave Bioreactor® bags aiming for a production capacity of up to 60 million doses of MVA vaccine per year. In addition to primary CEF culture, the potential use of cell lines could be of great interest to establish a robust and commercially viable manufacturing process with a controlled seed-lot system, full characterization of the production cells and a lower risk of introducing adventitious agents. For example, the CEF cell line DF-1 can be used to efficiently generate and amplify MVA vector viruses at the laboratory scale [54]. In addition, although MVA cannot productively replicate in most cell lines of mammalian origin, the virus has been found to efficiently multiply in the hamster kidney cell line BHK-21 [55,56] and, more recently, also in rat IEC-6 cells [57]. However, it still remains to be determined if these or other continuous cell lines fulfill the technical and regulatory requirements for development of a commercial manufacturing process for MVA vector vaccines.

MVA induces protective immunity against influenza virus infection

The potential of recombinant MVA to induce protective immunity was already demonstrated 15 years ago. A recombinant MVA was constructed that expressed the hemagglutinin (HA) and NP genes of influenza virus A/PR/8/34 (H1N1) under the control of the synthetic early/late vaccinia virus promoter sP [41]. A single immunization with 108 plaque-forming units (PFU) of MVA-HA-NP induced strong antibody responses that could be boosted by subsequent immunizations. Furthermore, a single immunization with as low as 105 PFU of MVA HA-NP afforded protection against a lethal challenge infection with influenza virus A/PR/8/34 4 weeks later. The protective immunity not only correlated with the induction of virus-specific antibodies but also with anamnestic cytotoxic T lymphocyte (CTL) responses detected in MVA-HA-NP-primed mice. Interestingly, the same MVA vector vaccine also provided protection against influenza challenge upon oral delivery [58]. The enteric administration of two doses (106 PFU) MVA-HA-NP elicited serum anti-H1 IgG and mucosal anti-H1 IgA antibodies and protected the upper and lower respiratory tract upon influenza virus challenge. Furthermore, vaccination with this MVA-HA-NP vaccine afforded enhanced recovery from infection with a heterosubtypic (H3N2) influenza A virus strain, which correlated with the induction of cross-reactive CTL responses in the vaccinated mice. More recently, recombinant MVA were constructed that express the HA genes of influenza A/H5N1 viruses A/Hong Kong/156/97 (A/HK/97) and A/Vietnam/1194/04 (A/VN/04), which originate from clades 0 and 1 of A/H5N1 viruses, respectively [59]. Expression of HA was under control of the vaccinia virus promoter PsynII. Initially, these MVA recombinants were evaluated in mice and, upon a single immunization with 105 PFU, both constructs proved to be immunogenic. However, higher antibody titers were achieved with the recombinant MVA expressing the HA of A/HK/97 (clade 0). After a second immunization, the homologous antibody titers against A/VN/04, in particular, increased, which crossreacted with influenza virus A/HK/97 but not with influenza virus A/Indonesia/5/05 (A/IND/05), a virus belonging to yet another clade (clade 2.1). However, MVA-HA-VN/04-vaccinated mice were not only fully protected against infection with the homologous strain but also against infection with influenza viruses A/HK/97 and A/ IND/05. Protective immunity was assessed by scoring clinical
signs of infections (e.g., weight loss), virus titers in the lungs and immunohistochemistry. By contrast, vaccination with MVA-HA-HK/97 only afforded protection against homologous challenge infection. Since promising results were obtained with MVA-HA-VN/04, this vaccine candidate was further evaluated in a nonhuman primate model \[60\]. To this end, cynomolgus macaques were immunized twice with MVA-HA-VN/04 and then challenged with influenza virus A/Vietnam/1194/04 (clade 1) or A/Indonesia/5/05 (clade 2.1) to assess the level of protective immunity.

Immunization with MVA-HA-VN/04 induced antibodies and prevented replication of both viruses used for challenge infection in the upper and lower respiratory tract and the development of fever and severe necrotizing broncho-interstitial pneumonia. Furthermore, vaccination was well tolerated and did not provoke a rise of body temperature in vaccinated animals. Therefore, MVA-HA-VN/04 is a promising vaccine candidate for the induction of protective immunity in humans against highly pathogenic H5N1 avian influenza viruses that originate from clades of antigenically distinct viruses. Based on these promising results obtained in mice and macaques, further development of recombinant MVA as pandemic influenza vaccine candidates seems warranted.

Collectively, recombinant MVA expressing selected influenza virus proteins are promising and attractive vaccine candidates for the induction of protective immunity against pandemic influenza. The production of vaccine seed strains is fairly easy and straightforward and production of vaccines might even be performed in a flexible way independent of embryonated chicken eggs in CEF. This may seem contradictory; however, CEF cells can be produced in advance and cryopreserved until use. If this is achievable at a large scale, production can start without delay as soon as the seed virus becomes available and independent of a source of embryonated chicken eggs, which

| Advantage | Implication for influenza vaccine production | Disadvantage | Implication for influenza vaccine production |
|-----------|-----------------------------------------------|--------------|-----------------------------------------------|
| Production | | | |
| Independent of embryonated chicken eggs, in (stockpiled) CEF cells | Flexible vaccine production | Use of primary/secondary CEF cells | Higher risk for adventitious agent contamination |
| Safe, BSL-1 conditions | Ease of manufacturing | | |
| Option to upscale | Increase production capacity | | |
| Efficacy | | | |
| Induction of strong antibody responses | Use of adjuvant is not required | High dose required | Increased costs |
| Induction of cross-reactive antibodies | Protection against antigenically distinct variants | | |
| Induction of T-cell responses | Possibility for broadly protective immunity | | |
| No interference by pre-existing vector immunity | Allows for repeated vaccination and induction of antibodies to multiple influenza virus antigens | | |
| Safety | | | |
| Replication deficiency and avirulence | Acceptable safety profile | | |
| Administration to immunocompromized individuals | Vaccination of these high-risk patients possible | | |
| Multivalent vaccines possible | Induction of virus-specific antibodies and T cell | Expression of multiple HA genes to induce broad protective antibody responses | |
| Stability | | | |
| Record for stability as lyophilized vaccine >4 weeks at 37°C | Stockpiling of vaccines possible | | |

*Taken from [61].
CEF: Chicken embryo fibroblast; HA: Hemagglutinin.
Candidate influenza vaccines based on recombinant MVA

Review

Expert commentary

During the last decade, the transmission of HPAI A viruses of the H5N1 subtype from infected poultry to humans has raised our awareness of our inadequate preparedness for the next influenza pandemic. The timely availability of safe and effective vaccines would be a cornerstone in controlling the impact of an influenza pandemic. However, the timely delivery of sufficient doses of effective and safe vaccines is a point of concern and has spurred the development of adjuvants that improve the immunogenicity of vaccines and that allow dose sparing and the development of novel production technologies. Recombinant MVA was recently evaluated preclinically as a viral vector for the delivery of the influenza A/H5N1 virus HA. The use of MVA-H5 induced protective immunity in mice and macaques against challenge infection with homologous and heterologous A/H5N1 influenza virus strains. Based on these results and the unique properties attributed to MVA, recombinant MVA expressing the influenza A/H5N1 virus hemagglutinin is a promising influenza vaccine candidate that could address most issues raised in association with pandemic influenza vaccine development, including timely delivery, production capacity, efficacy and safety. The promising results obtained in animal models warrant further evaluation and development of recombinant MVA-H5 as a pandemic influenza vaccine candidate.

Five-year view

Further evaluation of MVA-H5 in animal models and clinical Phase I/II/III trials is needed to confirm its suitability for use in humans. Based on the increasing clinical experience with MVA as a candidate third-generation smallpox vaccine and as an experimental vector vaccine against various other human diseases, it can be anticipated that a recombinant MVA-H5 vaccine will perform as is expected in humans and will be well tolerated. In addition, dose-finding experiments will assess the minimal dose required for the induction of protective immunity. Furthermore, the possibility to induce protective immunity by a single immunization with the MVA-H5 vaccines needs to be explored, which of course would be an ideal vaccination regimen in the face of a pandemic outbreak. In the long run, the MVA technology may be at the basis of a new generation of safe (pandemic) influenza vaccines that are immunogenic without the use of an adjuvant. To this end, the feasibility to produce MVA-based vaccines in a flexible way in CEFs at a large scale needs to be demonstrated.

Financial & competing interests disclosure

The authors are inventors on a patent application concerning the use of MVA-H5 as an influenza virus vaccine. The authors wish to acknowledge support from The Netherlands Influenza Vaccine Research Center (NIVAREC), ZonMW (grant 91402008), the European Commission (QLK2-CT2002-01034 NOVAFLU, LSHB-CT-2006-037536 MVACTOR) and the Forschungs-Sofortprogramm Influenza (FSI) of the Federal Government of Germany. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Key issues

- An influenza pandemic caused by influenza A viruses of the H5N1 subtype is imminent.
- To limit the impact of a future influenza pandemic, the timely availability of sufficiently efficacious and safe vaccines is highly desirable.
- Current influenza vaccine production capacity is limited, although the availability of adjuvants facilitates dose sparing and increase vaccine efficacy.
- Modified vaccinia virus Ankara (MVA)-based vaccines have been proven to be safe and efficacious and constitute a promising technology for the development of recombinant vaccines.
- A recombinant MVA expressing the hemagglutinin gene of influenza A/H5N1 viruses was immunogenic in mice and macaques and afforded protection against challenge infection with homologous and heterologous highly pathogenic avian influenza A/H5N1 viruses.
- The development and use of recombinant MVA-H5 could address most of the issues related to the production of a pandemic influenza vaccine and further clinical evaluation seems warranted.
References

Papers of special note have been highlighted as:
• of interest

1. Webster RG, Bean WJ. Evolution and ecology of influenza viruses: interspecies transmission. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, Oxford, UK 109–119 (1998).

2. Potter CW. Chronicle of influenza pandemics. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, Oxford, UK 3–18 (1998).

3. Claas EC, Osterhaus AD, van Beek R et al. Human influenza A HSN1 virus related to a highly pathogenic avian influenza virus. Lancet 351(9101), 472–477 (1998).

4. de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? Nature 389(6651), 554 (1997).

5. Subbarao K, Klimov A, Katz J et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279(5349), 393–396 (1998).

6. Olsen SJ, Unghusak K, Sovann L et al. Family clustering of avian influenza A (H5N1). N. Engl. J. Med. 352(4), 333–340 (2005).

7. Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg. Infect. Dis. 13(9), 1348–1353 (2007).

8. Kuiken T, Holmes EC, McCauley J et al. Host species barriers to influenza virus infections. Science 312(5772), 394–397 (2006).

9. Kreijtz JH, Osterhaus AD, Rimmelzwaan GF. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum. Vaccin. (Epub ahead of print) (2009).

10. Mayr A, Munz E. [Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures]. Zentralbl. Bakteriol. [Orig.], 195(1), 24–35 (1964).

11. Mayr A, Stickl H, Muller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism]. Zentralbl. Bakteriol. [B] 167(5–6), 375–390 (1978).

12. Stickl H, Hochstein-Mintzel V. Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (“MVA virus”). Munch. Med. Wochenschr. 113, 1194–1195 (1971).

13. Stickl H, Hochstein-Mintzel V, Mayr A et al. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA)]. Dtsch Med. Wochenschr. 99(47), 2386–2392 (1974).

14. Frey SE, Newman FK, Kennedy JS et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (modified vaccinia Ankara) followed by Dryvax challenge. Vaccine 25(51), 8562–8573 (2007).

15. Parrino J, McCurdy LH, Larkin BD et al. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals. Vaccine 25(8), 1513–1525 (2007).

16. Jones T, IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection. Curr. Opin. Mol. Ther. 10(4), 407–417 (2008).

17. Stittelaar KJ, Kuiken T, de Swart RL et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19(27), 3700–3709 (2001).

18. Demonstrates that modified vaccinia virus Ankara (MVA) can be used safely in immunocompromized nonhuman primates.

19. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA 89(22), 10847–10851 (1992).

20. First paper to describe MVA as a vector for the expression of foreign genes of interest.

21. Demonstrate the reactivity of vector with vectorial immunity to the vector.

22. Demonstrate the safety of vector in human beings.

23. Sandstrom E, Nilsson C, Hejedeman B et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198(10), 1482–1490 (2008).

24. Hawke J, Sibbitt TJ, Gelderbloem S et al. Safety and immunogenicity of a new tuberculosis vaccine, MVAS1, in healthy adults in South Africa. J. Infect. Dis. 198(4), 544–552 (2008).

25. Jaoko W, Nakwagala FN, Anzala O et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26(22), 2788–2795 (2008).

26. Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res.13(15 Pt 1), 4487–4494 (2007).

27. Acres B, Bonnefont YJ. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev. Vaccines 7(7), 889–893 (2008).

28. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74(16), 7651–7655 (2000).

29. Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother. 57(7), 977–986 (2008).

30. Sharpe S, Poyhanskaya N, Dennis M et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in thersus macaques by modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 82(Pt 9), 2215–2223 (2001).

31. Yang ZY, Wyatt LS, Kong WP et al. Treatment of chronic myeloid leukemia and pre-existing poxvirus immunity from modified vaccinia virus Ankara expressing SIV-specific CTL in thersus macaques by modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 82(Pt 9), 2215–2223 (2001).

32. Sandstrom E, Nilsson C, Hejedeman B et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198(10), 1482–1490 (2008).

33. Hawke J, Sibbitt TJ, Gelderbloem S et al. Safety and immunogenicity of a new tuberculosis vaccine, MVAS1, in healthy adults in South Africa. J. Infect. Dis. 198(4), 544–552 (2008).

34. Jaoko W, Nakwagala FN, Anzala O et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26(22), 2788–2795 (2008).

35. Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother. 57(7), 977–986 (2008).

36. Sharpe S, Poyhanskaya N, Dennis M et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in thersus macaques by modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 82(Pt 9), 2215–2223 (2001).

37. Yang ZY, Wyatt LS, Kong WP et al. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77(1), 799–803 (2003).

38. Naito T, Kaneko Y, Kozbor D. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. J. Gen. Virol. 88(Pt 1), 61–70 (2007).
33 Mooij P, Balia-Jhaghoorsingh SS, Koopman G et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. *J. Virol.* 82(6), 2975–2988 (2008).

34 Tatsis N, Lin SW, Harris-McCoy K et al. Multiple immunizations with adenovirus and MVA vectors improve CD8+ T-cell functionality and mucosal homing. *Virology* 367(1), 156–167 (2007).

35 Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western reserve strain and advantages as a vaccine. *J. Virol.* 74(2), 923–933 (2000).

36 Albrecht M, Suezey, Staib C et al. Vaccination with a modified vaccinia virus Ankara-based vaccine protects mice from allergic sensitization. *J. Gene Med.* 10(12), 1324–1333 (2008).

37 Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. *Nat. Med.* 4(4), 397–402 (1998).

38 El-Gogo S, Staib C, Lasarte JJ, Sutter G, Adler H. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. *J. Gene Med.* 10(2), 177–186 (2008).

39 Gasteiger J, Kastenmuller W, Ljapoci R, Sutter G, Drexler I. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. *J. Virol.* 81(21), 11925–11936 (2007).

40 Peters BS, Jaoko W, Vardas E et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. *Vaccine* 25(11), 2120–2127 (2007).

41 Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host-range restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. *Vaccine* 12(11), 1032–1040 (1994).

• Describes for the first time that with MVA, influenza virus-specific cellular and humoral immune responses can be induced that protect against infection.

42 Hirsch VM, Fuerst TR, Sutter G et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. *J. Virol.* 70(6), 3741–3752 (1996).

43 Pan R, Suezey Y, Lustig S et al. Post-exposure immunization with vaccinia virus MVA or conventional Lister vaccine provides solid protection in murine model for human smallpox. *J. Infect. Dis.* 199(1), 39–48 (2009).

44 Earl PL, Americo JL, Wyatt LS et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. *Proc. Natl Acad. Sci. USA* 105(31), 10889–10894 (2008).

45 Ferrier-Rembert A, Drillien R, Tourinen JN, Garin D, Crane JM. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. *Vaccine* 26(14), 1794–1804 (2008).

46 Waabler Z, Anzaghe M, Ludwig H et al. Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. *J. Virol.* 81(22), 12102–12110 (2007).

47 Samuelsson C, Hausmann J, Lauterbach H et al. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. *J. Clin. Invest.* 118(5), 1776–1784 (2006).

48 Guerra S, Najera JL, Gonzalez JM et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. *J. Virol.* 81(16), 8707–8721 (2007).

49 Lehmann MH, Kastenmuller W, Kandemir JD et al. Modified vaccinia virus Ankara (MVA) triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression. *J. Virol.* 83(6), 2540–2552 (2009).

50 Schnierle BS, Suezey Y, Sutter G. Recombinant poxvirus vaccines in biomedical research. In: *Poxviruses.* Mercer A, Schmidt A, Weber O (Eds), Birkhauser-Verl, Basel, Switzerland (2007).

51 Staib C, Lowel M, Erffle V, Sutter G. Improved host range selection for recombinant modified vaccinia virus Ankara. *Biotechniques* 34(4), 694–696, 698, 700 (2003).

52 Domi A, Moss B. Engineering of a vaccinia virus bacterial artificial chromosome in *Eoocheria coli* by bacteriophage λ-based recombination. *Nat. Methods* 2(2), 95–97 (2005).

53 Cottingham MG, Andersen RF, Spencer AJ et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). *PLoS ONE* 3(2), e1638 (2008).

54 Chavan R, Marfatia KA, An IC, Garber DA, Feinberg MB. Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses. *J. Virol.* 80(15), 7676–7687 (2006).

55 Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. *Virology* 258(2), 198–211 (1997).

56 Drexler I, Keller K, Wahren B, Erle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. *J. Gen. Virol.* 79(Pt 2), 347–352 (1998).

57 Okeke MI, Nilssen O, Traavik T. Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines. *J. Gen. Virol.* 87(Pt 1), 21–27 (2006).

58 Bender BS, Rowe CA, Taylor SF et al. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. *J. Virol.* 70(9), 6418–6424 (1996).

59 Kreijtz JH, Suezey Y, van Amerongen G et al. Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. *J. Infect. Dis.* 195(11), 1598–1606 (2007).

• Demonstrates that with MVA protective immunity can be induced against a lethal challenge with homologous and heterologous influenza A/H5N1 viruses.

60 Kreijtz JHC, Suezey Y, de Mutsert G et al. Recombinant modified vaccinia virus Ankara expressing HA confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. *J. Infect. Dis.* 199(3), 405–413 (2009).
• Shows that the results obtained in the mouse model can be reproduced in nonhuman primates confirming that recombinant MVA-H5 is a promising influenza virus H5N1 vaccine candidate.

61 Just I, Finke H. [A contribution to the stabilisation of the MVA-vaccine]. Zentralbl. Bakteriol. [Orig. A], 245(3), 276–282 (1979).

Websites

101 WHO cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO

www.who.int/csr/disease/avian_influenza/country/cases_table_2008_09_10/en/index.html

102 WHO options for the use of human H5N1 influenza vaccines and the WHO H5N1 vaccine stockpile

www.who.int/csr/resources/publications/who_hse_epr_gip_2008_1d.pdf

103 WHO Antigenic and genetic characteristics of H5N1 viruses and candidate H5N1 vaccine viruses developed for potential use as human vaccines

www.who.int/csr/disease/avian_influenza/guidelines/200809_H5VaccineVirusUpdate.pdf

104 Bavarian Nordic

www.bavarian-nordic.com

Affiliations

• Guus F Rimmelzwaan
Erasmus Medical Center, Department of Virology, Rotterdam, The Netherlands
Tel.: +31 107 044 066
Fax: +31 107 044 760
g.rimmelzwaan@erasmusmc.nl

• Gerd Sutter
Paul-Ehrlich-Institut, Department of Virology, Langen, Germany
sutge@pei.de